REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

The Healer

Recoverybeginner
12
Peptides

2

Avg Daily mcg

0

Level

beginner

Added

May 7, 2026

Overview

The Healer is a foundational recovery stack built on the two most well-researched tissue repair peptides in the field. Designed for beginners entering the world of peptide therapy, this straightforward two-peptide protocol delivers powerful regenerative signaling without the complexity of advanced multi-compound stacks. It represents the essential starting point for anyone seeking accelerated recovery from injuries, chronic pain conditions, or general tissue wear. BPC-157, administered at 250mcg subcutaneously once daily, is a body protection compound originally isolated from human gastric juice. This 15-amino-acid peptide has accumulated an impressive body of preclinical research demonstrating its ability to heal virtually every tissue type studied, including muscle, tendon, ligament, bone, intestinal lining, and neural tissue. It works through multiple pathways: promoting angiogenesis via VEGF upregulation, accelerating fibroblast migration to injury sites, modulating nitric oxide systems for improved blood flow, and protecting cells from oxidative damage. Daily subcutaneous administration near an injury site provides consistent local tissue concentrations for optimal repair signaling. TB-500, dosed at 2.5mg subcutaneously twice weekly, is a synthetic version of the active region of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in tissue repair throughout the body. TB-500 promotes healing by upregulating actin polymerization, which enhances cell migration and proliferation at injury sites. Unlike BPC-157, TB-500 distributes systemically regardless of injection location, making it effective for diffuse or hard-to-reach injuries. It also exhibits significant anti-inflammatory properties and has been shown to reduce scar tissue formation, promoting more functional tissue restoration. The synergy between these two peptides is well-established in the peptide therapy community. BPC-157 provides targeted local repair amplification while TB-500 creates a systemic pro-healing environment. Together they address injuries from multiple angles: inflammation reduction, blood vessel formation, cell migration, and structural protein synthesis. This stack is ideal for athletes recovering from training injuries, individuals with chronic musculoskeletal pain, or anyone experiencing slow healing. The protocol runs for 4-8 weeks depending on injury severity. No complex cycling is required, making it the perfect entry point for peptide therapy newcomers. Subcutaneous injection technique is simple to learn and well-tolerated.

Dosing Protocol

BPC-157

Every day· subcutaneous

250mcg

per dose

TB-500

Twice per week· subcutaneous

2.5mg

per dose

Goals & Evidence

Evidence tier:community

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.